Management of Glycemia in Patients With Diabetes Mellitus and CKD

American Journal of Kidney Diseases

Volumn 50, Issue 5, 2007, Pages 865-879

  Lubowsky, Noah D ^a   Siegel, Richard ^a   Pittas, Anastassios G ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

chronic kidney disease; Diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN SENSITIZING AGENT; ISOPHANE INSULIN; LISINOPRIL; METFORMIN; MIGLITOL; NATEGLINIDE; PRAMLINTIDE; REPAGLINIDE; SIMVASTATIN; SITAGLIPTIN; SULFONYLUREA;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CASE REPORT; CHRONIC KIDNEY DISEASE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN TREATMENT; LABORATORY TEST; MALE; MICROALBUMINURIA; NAUSEA; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERITONEAL DIALYSIS; RENAL REPLACEMENT THERAPY; SYMPTOMATOLOGY;

DIABETIC NEPHROPATHIES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; POSTOPERATIVE PERIOD; RENAL DIALYSIS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 35348917135     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.08.012     Document Type: Article

References (86)

1. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 49 suppl 2 (2007) S12-S154
2. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289 (2003) 76-79
3. US Renal Data System. USRDS 2003 Annual Data Report (2003), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
4. Muntner P., Coresh J., Powe N.R., and Klag M.J. The contribution of increased diabetes prevalence and improved myocardial infarction and stroke survival to the increase in treated end-stage renal disease. J Am Soc Nephrol 14 (2003) 1568-1577
5. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. [see comments]. N Engl J Med 329 (1993) 977-986
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
7. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
8. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 28 (1995) 103-117
9. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
10. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 30 suppl 1 (2007) S4-S41
11. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. Endocr Pract 8 (2002) 5-11
12. Rossing K., Christensen P.K., Hovind P., Tarnow L., Rossing P., and Parving H.H. Progression of nephropathy in type 2 diabetic patients. Kidney Int 66 (2004) 1596-1605
13. Hovind P., Rossing P., Tarnow L., Smidt U.M., and Parving H.H. Progression of diabetic nephropathy. Kidney Int 59 (2001) 702-709
14. Fioretto P., Bruseghin M., Berto I., Gallina P., Manzato E., and Mussap M. Renal protection in diabetes: Role of glycemic control. J Am Soc Nephrol 17 suppl 2 (2006) S86-S89
15. Menon V., Greene T., Pereira A.A., et al. Glycosylated hemoglobin and mortality in patients with nondiabetic chronic kidney disease. J Am Soc Nephrol 16 (2005) 3411-3417
16. McMurray S.D., Johnson G., Davis S., and McDougall K. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis 40 (2002) 566-575
17. Tanaka Y., Atsumi Y., Matsuoka K., Onuma T., Tohjima T., and Kawamori R. Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients. Diabetes Care 21 (1998) 116-120
18. Feldt-Rasmussen B. Is there a need to optimize glycemic control in hemodialyzed diabetic patients?. Kidney Int 70 (2006) 1392-1394
19. Oomichi T., Emoto M., Tabata T., et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: A 7-year observational study. Diabetes Care 29 (2006) 1496-1500
20. Morioka T., Emoto M., Tabata T., et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 24 (2001) 909-913
21. Wu M.S., Yu C.C., Yang C.W., et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 12 (1997) 2105-2110
22. Williams M.E., Lacson Jr. E., Teng M., Ofsthun N., and Lazarus J.M. Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int 70 (2006) 1503-1509
23. Kalantar-Zadeh K., Kopple J.D., Regidor D.L., et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care 30 (2007) 1049-1055
24. Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67 (2005) 2089-2100
25. Rubenfeld S., and Garber A.J. Abnormal carbohydrate metabolism in chronic renal failure. The potential role of accelerated glucose production, increased gluconeogenesis, and impaired glucose disposal. J Clin Invest 62 (1978) 20-28
26. Kobayashi S., Maesato K., Moriya H., Ohtake T., and Ikeda T. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 45 (2005) 275-280
27. Stumvoll M. Glucose production by the human kidney-Its importance has been underestimated. Nephrol Dial Transplant 13 (1998) 2996-2999
28. Rave K., Heise T., Pfutzner A., Heinemann L., and Sawicki P.T. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care 24 (2001) 886-890
29. Biesenbach G., Raml A., Schmekal B., and Eichbauer-Sturm G. Decreased insulin requirement in relation to GFR in nephropathic type 1 and insulin-treated type 2 diabetic patients. Diabet Med 20 (2003) 642-645
30. Sechi L.A., Catena C., Zingaro L., Melis A., and De Marchi S. Abnormalities of glucose metabolism in patients with early renal failure. Diabetes 51 (2002) 1226-1232
31. Bannon P., Lessard F., Lepage R., Joly J.G., and Dufresne L. Glycated hemoglobin in uremic patients as measured by affinity and ion-exchange chromatography. Clin Chem 30 (1984) 485-486
32. Little R.R., Tennill A.L., Rohlfing C., et al. Can glycohemoglobin be used to assess glycemic control in patients with chronic renal failure?. Clin Chem 48 (2002) 784-786
33. Nakao T., Matsumoto H., Okada T., et al. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med (Tokyo, Japan) 37 (1998) 826-830
34. Pi-Sunyer X., Blackburn G., Brancati F.L., et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: One-year results of the look AHEAD trial. Diabetes Care 30 (2007) 1374-1383
35. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443
36. Stenman S., Melander A., Groop P.H., and Groop L.C. What is the benefit of increasing the sulfonylurea dose?. Ann Intern Med 118 (1993) 169-172
37. Brier M.E., Bays H., Sloan R., Stalker D.J., Welshman I., and Aronoff G.R. Pharmacokinetics of oral glyburide in subjects with non-insulin-dependent diabetes mellitus and renal failure. Am J Kidney Dis 29 (1997) 907-911
38. Jonsson A., Rydberg T., Sterner G., and Melander A. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 53 (1998) 429-435
39. Rydberg T., Jonsson A., Roder M., and Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 17 (1994) 1026-1030
40. Krepinsky J., Ingram A.J., and Clase C.M. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 35 (2000) 500-505
41. Aventis: Prescribing information for Amaryl. Aventis, Bridgewater, NJ, 2007
42. Rosenkranz B., Profozic V., Metelko Z., Mrzljak V., Lange C., and Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 39 (1996) 1617-1624
43. Asplund K., Wiholm B.E., and Lundman B. Severe hypoglycaemia during treatment with glipizide. Diabet Med 8 (1991) 726-731
44. Holstein A., Plaschke A., Hammer C., and Egberts E.H. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol 59 (2003) 91-97
45. Balant L., Zahnd G., Gorgia A., Schwarz R., and Fabre J. Pharmacokinetics of glipizide in man: Influence of renal insufficiency. Diabetologia 9 (1973) 331-338
46. Snyder R.W., and Berns J.S. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 17 (2004) 365-370
47. Prescribing information for Prandin (2007), Novo Nordisk, Princeton, NJ
48. Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 26 (2003) 886-891
49. Prescribing information for Starlix (2007), Novartis, East Hanover, NJ
50. Nagai T., Imamura M., Iizuka K., and Mori M. Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract 59 (2003) 191-194
51. Inoue T., Shibahara N., Miyagawa K., et al. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 60 (2003) 90-95
52. Drucker D.J., and Nauck M.A. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
53. Amori R.E., Lau J., and Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 298 (2007) 194-206
54. Lilly: Prescribing information for Byetta. Amylin Pharmaceuticals, San Diego, CA, 2007
55. Merck: Prescribing information for Januvia. Merck, Whitehouse Station, NJ, 2007
56. Bergman A.J., Cote J., Yi B., et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 30 (2007) 1862-1864
57. Ryan G.J., Jobe L.J., and Martin R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther 27 (2005) 1500-1512
58. Prescribing information for Symlin (2007), Amylin Pharmaceuticals, San Diego, CA
59. Kirpichnikov D., McFarlane S.I., and Sowers J.R. Metformin: An update. Ann Intern Med 137 (2002) 25-33
60. Nathan D.M., Buse J.B., Davidson M.B., et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2006) 1963-1972
61. Salpeter S., Greyber E., Pasternak G., and Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews (Online) (2006) CD002967
62. Lilly: Prescribing information for Actos. Pharmaceuticals America, Inc, Lincolnshire, IL, 2007
63. Glaxo Smith Kline: Prescribing information for Avandia. Glaxo Smith Kline, Research Triangle Park, NC, 2007
64. Budde K., Neumayer H.H., Fritsche L., Sulowicz W., Stompor T., and Eckland D. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 55 (2003) 368-374
65. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
66. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes-An interim analysis. N Engl J Med 357 (2007) 28-38
67. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., and Laakso M. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 359 (2002) 2072-2077
68. Bayer Corp: Prescribing information for Precose. West Haven, CT, Bayer Corp, 2007
69. Pharmacia: Prescribing information for Glyset. Kalamazoo, MI, Pharmacia, 2007
70. Peyrot M., Rubin R.R., Lauritzen T., et al. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) Study. Diabetes Care 28 (2005) 2673-2679
71. Mooradian A.D., Bernbaum M., and Albert S.G. Narrative review: A rational approach to starting insulin therapy. Ann Intern Med 145 (2006) 125-134
72. Ceglia L., Lau J., and Pittas A.G. Meta-analysis: Efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med 145 (2006) 665-675
73. Pfizer: Prescribing information for Exubera. Pfizer, New York, NY, 2007
74. Montori V.M., Basu A., Erwin P.J., Velosa J.A., Gabriel S.E., and Kudva Y.C. Posttransplantation diabetes: A systematic review of the literature. Diabetes Care 25 (2002) 583-592
75. Markell M. New-onset diabetes mellitus in transplant patients: Pathogenesis, complications, and management. Am J Kidney Dis 43 (2004) 953-965
76. Hur K.Y., Kim M.S., Kim Y.S., et al. Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care 30 (2007) 609-615
77. Davidson J., Wilkinson A., Dantal J., et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an International Expert Panel Meeting. Barcelona, Spain, 19 February 2003. Transplantation 75 suppl (2003) S3-S24
78. Hricik D.E., Bartucci M.R., Moir E.J., Mayes J.T., and Schulak J.A. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 51 (1991) 374-377
79. Turk T., Pietruck F., Dolff S., et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant 6 (2006) 842-846
80. Pietruck F., Kribben A., Van T.N., et al. Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation. Transpl Int 18 (2005) 483-486
81. Luther P., and Baldwin Jr. D. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 4 (2004) 2135-2138
82. Nevalainen P.I., Lahtela J.T., Mustonen J., and Pasternack A. Subcutaneous and intraperitoneal insulin therapy in diabetic patients on CAPD. Perit Dial Int 16 suppl 1 (1996) S288-S291
83. Johnson C., and Simmons W.D. Dialysis of Drugs (2006), Nephrology Pharmacy Associates, Inc, USA
84. Quellhorst E. Insulin therapy during peritoneal dialysis: Pros and cons of various forms of administration. J Am Soc Nephrol 13 suppl 1 (2002) S92-S96
85. Manske C.L. Hyperglycemia and intensive glycemic control in diabetic patients with chronic renal disease. Am J Kidney Dis 32 suppl 3 (1998) S157-S171
86. Wong T.Y., Szeto C.C., Chow K.M., Leung C.B., Lam C.W., and Li P.K. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 46 (2005) 713-719